YEAR

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018

PROGRAMS

  • All
  • ALG-000184
  • ALG-055009
  • ALG-097558
  • Preclinical
  • Publications
  • Other
September 2025

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development
September 2025

The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments

International HBV Meeting 2025
September 2025

Antisense oligonucleotide-based strategy to target hepatitis delta virus infections

International HBV Meeting 2025
September 2025

A Syrian hamster model of persistent HDV infection

International HBV Meeting 2025
September 2025

Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro

International HBV Meeting 2025
September 2025

Capsid assembly modulators bind and directly target HBeAg

International HBV Meeting 2025
September 2025

PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells

International HBV Meeting 2025
July 2025

Antisense oligonucleotides as drugs with both direct and indirect antiviral actions

Antiviral Research
June 2025

Discovery and Preclinical Profile of ALG-097558, a Pan-Coronavirus 3CLpro Inhibitor

Journal of Medicinal Chemistry
May 2025

European Association for the Study of the Liver Congress (EASL) 2025 Satellite Symposium Recording

EASL 2025
May 2025

Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints 

EASL 2025
May 2025

ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice 

EASL 2025
May 2025

Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates 

EASL 2025
May 2025

ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD Study

EASL 2025
May 2025

Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection 

EASL 2025
May 2025

The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection 

EASL 2025
May 2025

Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184 

EASL 2025
May 2025

ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study 

EASL 2025
March 2025

ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Randomized, Double-Blind, Placebo-controlled Phase 2a HERALD Study

APASL 2025
March 2025

Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in High Viral Suppression Rates in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection

APASL 2025
March 2025

Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in Rapid Viral Load Reduction and High Viral Suppression Rates in Untreated HBeAg-Negative Subjects with Chronic Hepatitis B Virus Infection

APASL 2025
November 2024

The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075

Journal of Medicinal Chemisty
November 2024

ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2

AASLD 2024
November 2024

Nonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

AASLD 2024
November 2024

Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection

AASLD 2024
November 2024

Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro

AASLD 2024
November 2024

Discovery and Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancer

SITC 2024
October 2024

Two Pre-clinical Short Interfering RNA (siRNA) Molecules Targeting Human HSD17β13 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Oligonucleotide Therapeutic Society (OTS) Annual Meeting 2024
October 2024

Discovery and Optimization of the Pre-Clinical Efficacy of Human PNPLA3-Targeting Short Interfering RNA Molecules (siRNAs) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis 

Oligonucleotide Therapeutic Society (OTS) Annual Meeting 2024
September 2024

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone

Journal of Medicinal Chemistry (2024)
June 2024

Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels

EASL 2024
June 2024

Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends

EASL 2024
June 2024

Association of Baseline Characteristics and Plasma ALG-001075 to HBsAg Responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment

EASL 2024
June 2024

In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis

EASL 2024
June 2024

Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles

EASL 2024
June 2024

Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs

EASL 2024
April 2024

Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers

ESCMID 2024
April 2024

An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients

Antiviral Research (2024), 224, 105835
March 2024

ALG-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian HBeAg-Negative CHB Subjects

APASL 2024
March 2024

ALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB

APASL 2024
March 2024

ALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB

APASL 2024
March 2024

Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a THR β Agonist, in Hyperlipidemic Subjects

APASL 2024
December 2023

Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs)

Bioorganic Chemistry (2023), 141, 106923
December 2023

Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg

HEP DART 2023
December 2023

Class-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response

AASLD 2023
December 2023

Discovery of a Liver Targeted Oral PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer

AASLD 2023
December 2023

Nonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

AASLD 2023
December 2023

Preclinical Resistance Profile and Antiviral Activity of the Best-in-Class CAM-E ALG-001075, the Parent Compound of ALG-000184

AASLD 2023
December 2023

Safety, Pharmacokinetics, And Pharmacodynamics Of Multiple Ascending Oral Doses Of ALG-055009, A Thyroid Hormone Receptor Beta Agonist, In Hyperlipidaemic Subjects And Relative Bioavailability/food Effect Of A Solid Formulation In Healthy Volunteers

AASLD 2023
December 2023

Prolonged (>24 Week) Dosing with the Oral CAM-E Compound ALG-000184 Results In Multi-log Reductions In Hepatitis B Surface Antigen, HBV DNA, And HBV RNA Levels In Untreated E Antigen Postive Subjects With Chronic Hepatitis B

AASLD 2023
November 2023

Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models

International Journal of Molecular Sciences (2023), 24(22), 16274
November 2023

LONG-TERM DOSING WITH THE CAPSID ASSEMBLY MODULATOR ALG-000184 RESULTS IN MULTI-LOG REDUCTIONS OF DNA, RNA, HBsAg, HBeAg AND HBcrAg IN UNTREATED HBeAg POSITIVE CHRONIC HEPATITIS B SUBJECTS

AASLD 2023
November 2023

Discovery of ALG-093989, a Highly Potent and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Cancers

SITC 2023
November 2023

Discovery of ALG-094103, a Liver-Targeted and Orally Bioavailable Small Molecule PD-L1 Inhibitor for the Treatment of Liver Cancer

SITC 2023
October 2023

Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation

Hepatology (2023)
September 2023

Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles

J Virol. 2023, 97(10), e0072223
August 2023

Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies

Antiviral Research (2023), 216, 105670
June 2023

CAM-E ALG-000184, Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B

EASL 2023
June 2023

siRNA ALG-125755, Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B

EASL 2023
June 2023

siRNA ALG-125755, Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver

EASL 2023
June 2023

Small molecule PD-L1 inhibitor ALG-093702, Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models

EASL 2023
June 2023

siRNA PD-L1 inhibitor, A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice

EASL 2023
June 2023

Hepatitis B virus model system, An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients

EASL 2023
June 2023

Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma

EASL 2023
May 2023

Preclinical Antiviral Profile of ALG-097558, a Novel Pan-Coronavirus 3CL Protease Inhibitor

ISIRV-AVG 2023
April 2023

Treatment for >12 Weeks with the Capsid Assembly Modulator (CAM) ALG-000184 and Entecavir (ETV) Dose Dependently Reduces HBsAg in HBeAg+ Subjects with Chronic Hepatitis B (CHB)

GHS 2023
February 2023

Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA (siRNA), in Healthy Volunteers (HV)

APASL 2023
February 2023

ALG-000184, an Orally Administered Capsid Assembly Modulator (CAM) Reduces HBsAg in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)

APASL 2023
February 2023

Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer

APASL 2023
February 2023

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia

APASL 2023
February 2023

Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG‑001075

APASL 2023
February 2023

The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT

APASL 2023
February 2023

Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBV

APASL 2023
February 2023

ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection

APASL 2023
January 2023

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

mBio (2023), e0281522
December 2022

Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19

Respi DART 2022
December 2022

The Prodrug of a Novel Capsid Assembly Modulator (CAM), ALG-000184, Demonstrates a Favorable Nonclinical Toxicokinetic and Toxicology Profile for the Treatment of Chronic Hepatitis B (CHB)

Respi DART 2022
November 2022

Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers

AASLD 2022
November 2022

Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)

AASLD 2022
November 2022

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, in Hyperlipidaemic Subjects

AASLD 2022
November 2022

Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG-125755, a GalNAc conjugated siRNA, for functional cure of chronic hepatitis B

AASLD 2022
November 2022

HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation

AASLD 2022
November 2022

Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action

AASLD 2022
November 2022

Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV

AASLD 2022
November 2022

Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development

ICAR 2022
November 2022

Mutations L50F, E166A and L167F in SARS-CoV-2 3CLpro are Selected by a Protease Inhibitor In Vitro and are Associated with Resistance

ICAR 2022
November 2022

Discovery of Highly Potent Oligonucleotides Targeting SARS-CoV-2

ICAR 2022
October 2022

SARS-CoV-2 Viruses with Cross-Resistance to 3CLpro Inhibitors can be Selected In Vitro, and can Replicate and Transmit in a Hamster Model

Keystone Symposium 2022
October 2022

Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model

Keystone Symposium 2022
October 2022

Nomenclature of HBV core protein-targeting antivirals

Nature Reviews Gastroenterology & Hepatology (2022), 19(12), 748
September 2022

Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model

OPTIONS XI 2022
September 2022

Oral 3CL-Protease Inhibitors for Treating Coronaviral Infections

DOT 2022
June 2022

Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia

EASL 2022
June 2022

Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B

EASL 2022
June 2022

Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model

EASL 2022
June 2022

The HBV siRNA, ALG-125755, demonstrates a favorable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model

EASL 2022
June 2022

Discovery of oral PD-L1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B

EASL 2022
May 2022

Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex

Molecules (2022), 27(9), 2918
March 2022

Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non-Asian Subjects with Chronic Hepatitis B (CHB)

APASL 2022
March 2022

Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non Asian Subjects with Chronic Hepatitis B (CHB)

APASL 2022
March 2022

Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG-125755 in HBV Infected Cells and the AAV HBV Mouse Model

APASL 2022
March 2022

Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives

Journal of Clinical Medicine (2022), 11(5), 1349
November 2021

Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB)

AASLD 2021
November 2021

Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model

AASLD 2021
November 2021

Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics

AASLD 2021
November 2021

Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH

AASLD 2021
November 2021

ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo

AASLD 2021
August 2021

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection

Current Opinion in Virology (2021), 49, 36-40
July 2021

Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry

SLAS Discovery (2021), 26(6), 766-774
June 2021

ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model

EASL 2021
June 2021

Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity

EASL 2021
June 2021

Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity of Multiple Doses of ALG-000184 in Healthy Volunteers (HV) and Subjects with Chronic Hepatitis B (CHB)

HBV-TAG 2021
May 2021

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

Biochemical and Biophysical Research Communications (2021), 555, 134-139
May 2021

Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics

PNAS (2021), 118(21), e2010718118
March 2021

The 3CLpro™ Inhibitor ALG-097111 Potently Inhibits SARS-CoV-2 Replication in Hamsters

CROI 2021
March 2021

Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development

Antiviral Research (2021), 187, 105020
February 2021

Genome Sequences and Phylogeny of Two Duck Hepatitis B Viruses

Microbiology Resource Announcements (2021), 10(7), e01327
February 2021

Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ALG-000184, a Class II Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B (CHB), in Healthy Volunteers (HV)

APASL 2021
February 2021

Excellent preclinical characteristics of ALG-000184, a prodrug of the HBV capsid assembly modulator ALG-001075

APASL 2021
December 2020

Structure-based discovery of potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitors using a multiplex screening platform

RespiDART 2020
December 2020

Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)

PLoS One (2020), 15(12), e0240338
November 2020

ALG-055009, a potent, selective THR-β agonist for treatment of NASH, demonstrates significant cholesterol reduction in a Diet-Induced Obese (DIO) mouse efficacy model

AASLD 2020
November 2020

Best-in-class preclinical characteristics of ALG-000184, a prodrug of the capsid assembly modulator ALG-001075 for the treatment of chronic hepatitis B

AASLD 2020
November 2020

Characterization of thyroid hormone receptor agonists for the treatment of NASH by quantification of gene transcription in human hepatocytes

AASLD 2020
November 2020

Tumor regression in a mouse model of hepatocellular carcinoma upon treatment with the STING agonist ALG-031048

AASLD 2020
October 2020

Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.

Antiviral Research (2020), 182, 104924
August 2020

ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B

EASL 2020
August 2020

Molecular, cellular and pharmacological characterization of beta selective partial agonists of human thyroid hormone receptor for the treatment of nonalcoholic steatohepatitis

EASL 2020
December 2019

Combination Approaches Towards a Functional Cure for Chronic Hepatitis B

HEP DART 2019
November 2019

Preclinical Development of ALG-055009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH

AASLD 2019
November 2019

Preclinical Assessment of Potency and Efficacy of a Novel Class-II Capsid Assembly Modulator, ALG-001024

AASLD 2019
November 2019

Preclinical Assessment of a Novel Capsid Assembly Modulator, ALG-001075, Demonstrates Best-in-Class In Vitro Potency and In Vivo Antiviral Efficacy

AASLD 2019
December 2018

Synthesis of Protected Amino Hexitol Nucleosides as Building Blocks for Oligonucleotide Synthesis

Journal of Organic Chemistry (2018), 83(24), 15155